A 55-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two prior lines achieves complete remission with axicabtagene ciloleucel (axi-cel). This CAR-T product targets which antigen and was evaluated in which landmark trial?

• A CD20; JULIET trial
• B CD38; CARTITUDE-1 trial
• C BCMA; KarMMa trial
• D CD19; ZUMA-1 trial ✓

Explanation

Axi-cel (axicabtagene ciloleucel, Yescarta) is a CD19-directed CAR-T cell therapy approved for relapsed/refractory DLBCL following the ZUMA-1 trial, which demonstrated ~82% overall response rate and ~54% complete remission rate in a heavily pre-treated population. JULIET evaluated tisagenlecleucel (also CD19-directed) in DLBCL. CARTITUDE-1 assessed ciltacabtagene autoleucel (BCMA-directed) in multiple myeloma; KarMMa evaluated idecabtagene vicleucel (BCMA-directed) in myeloma.

Reference: Robbins & Cotran Pathologic Basis of Disease, 10th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.